Health International

Pfizer ends COVID-19 trial with 95% efficacy

Pfizer Inc said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine showed it was 95% effective, adding it had the required two-months of safety data and would apply for emergency U.S. authorization within days.

The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90% effective. Moderna Inc on Monday released preliminary data for its vaccine, showing similar effectiveness.

Pfizer shares rose 3% to $37.19 and U.S.-listed shares of partner BioNTech SE were up 8% at $94.80 in premarket trading.

error: Content is protected !!